ADDF Invests $3m in Vaccinex Contingent for Alzheimer’s Disease Contingent on IRB Approval & Enrollment Milestones

ADDF Invests $3m in Vaccinex Contingent for Alzheimer’s Disease Contingent on IRB Approval & Enrollment Milestones

The Alzheimer’s Drug Discovery Foundation (ADDF) has granted an award, in the form of an investment of up to approximately $3 million in Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and...

Pin It on Pinterest